Skip to main content

Table 3 Patient demographics and baseline disease characteristics*

From: Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

Characteristic

Patients (N = 45)

Median (range) age, years

70 (48–85)

 45–< 65, n (%)

8 (17.8)

 65–< 75, n (%)

21 (46.7)

 ≥ 75, n (%)

16 (35.6)

Sex, n (%)

 Male

24 (53.3)

 Female

21 (46.7)

Race, n (%)

 White

43 (95.6)

 Black

1 (2.2)

 Other

1 (2.2)

Median (range) height, cm

168 (152–193)

Median (range) weight, kg

74 (46–114)

Type of MF, n (%)

 PMF

25 (55.6)

 PPV-MF

13 (28.9)

 PET-MF

7 (15.6)

Median (range) spleen volume, cm3

1798.5 (763.2–6633.4)

Median (range) palpable spleen length below costal margin, cm

13 (0–34)

Prior hydroxyurea use, n (%)

29 (64.4)

ECOG performance status, n (%)

 0

17 (37.8)

 1

20 (44.4)

 2

7 (15.6)

 3

1 (2.2)

DIPSS score, n (%)

 High risk (5–6)

6 (13.3)

 Intermediate-2 (3–4)

7 (15.6)

 Intermediate-1 (1–2)

31 (68.9)

 Low (0)

1 (2.2)

Transfusion status, n (%)

 Independent

30 (66.7)

 Dependent

15 (33.3)

JAK2 mutation status, n (%)

 Present

29 (64.4)

 Absent

15 (33.3)

Median (range) V617F at baseline for patients with JAK2 mutation, %§

77 (1–96)

  1. DIPSS Dynamic International Prognostic Scoring System, ECOG Eastern Cooperative Oncology Group, JAK Janus kinase, MF myelofibrosis, PET-MF post-essential thrombocythemia myelofibrosis, PMF primary myelofibrosis, PPV-MF post-polycythemia vera myelofibrosis
  2. *Intent-to-treat population
  3. n = 42
  4. One patient had a missing baseline value for JAK mutation status
  5. §n = 29